WP8 Immune Monitoring

Immune Monitoring

Work package objectives:

WP8 will focus on compiling, and establishing a comprehensive catalogue of standardised immunological and genetic assays for COVID-19 vaccines that can be rolled out across the network. This enables a direct comparison of results from different laboratories which in turn facilitates the design and implementation of multi-site clinical trials. The catalogue will include standardised assay protocols for humoral, cellular, mucosal immune monitoring, and assays for genetic variants. The team aims to align and standardise protocols, reagents, and standards (such as international antibody standards from NIBCS) with other major initiatives and networks such as CEPI’s consortium of centralised COVID-19 labs, WHO’s ACT Accelerator and NIH’s Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV). The team will also review available scientific data to identify and prioritise additional immune monitoring assays that should be developed in the future.

WP Leads:

Prof. Jean-Daniel Lelièvre

Institut national de la santé et de la recherche médicale (INSERM), France

 

Prof. Ole F. Olesen

European Vaccine Initiative (EVI), Germany

Work Package Results and Protocols

Flow Cytometry based-Live SARS-CoV-2 Micro-Neutralisation assay
Dr. Virginie Gautier, Associate professor in Virology, Centre for Experimental Pathogen Host Research (CEPHR), School of Medicine, University College Dublin (UCD), Ireland

Protocol for Cellular Immune Response Assays (Institute of Health Carlos III)
Dr. Jordi Ochando

Protocol for Humoral Immune Response Assays (University of Bergen)
Prof. Rebecca Jane Cox Brokstad

Protocol for the Collection and Handling of Biological Materials
WP4

Anti-Sars-Cov-2 (Spike, Nucleocapsid and RBD) IgG Protocol for MSD Platform
Alejandro Abner Garcia Leon (UCD Dublin School of Medicine)

Protocol on the Preparation of PBMCs
WP4

Protocol on Whole Blood Processing
(WP4)

Protocol on Sample Handling (WP4)